Rachelle Jacques Takes the Helm: Can Fresh Leadership Accelerate Corbus Pharma's Clinical Comeback?

Corbus Pharmaceuticals Holdings Inc. has named Rachelle Jacques as its new Board Chair, effective mid-May 2025, marking a significant leadership shift at the clinical-stage biopharmaceutical company. The appointment comes as the company enters a critical period, with three pipeline drug candidates approaching major clinical readout data expected later this year. Jacques succeeds Alan Holmer, who maintained his position on the Board after more than a decade as the founding Chair.

Who is Rachelle Jacques, and Why Does She Matter?

Rachelle Jacques isn’t your typical biotech executive. With over 25 years of experience navigating the complex landscape of biopharmaceuticals, she has built a track record that spans CEO roles, commercial strategy, financial operations, and everything in between. Before joining Corbus’ Board six years ago, Jacques led Enzyvant Therapeutics as CEO, where she championed the U.S. Food and Drug Administration approval of RETHYMIC®—one of the first three therapies to receive the prestigious Regenerative Medicine Advanced Therapy (RMAT) designation.

Her résumé reads like a who’s who of pharmaceutical leadership. At Alexion Pharmaceuticals, she headed the global complement franchise, overseeing commercialization strategy across hematology, nephrology, and neurology. She’s also held executive positions at Baxalta and its parent company Baxter International, managing everything from business operations to finance. Currently, Jacques serves on the board of uniQure N.V., a biotech firm developing gene therapies for rare genetic diseases. That combination of gene therapy exposure and rare disease expertise may prove particularly valuable as Corbus navigates its developmental challenges.

A Timely Transition at a Critical Moment

The leadership change at Corbus raises an interesting question: why now? The timing suggests more than routine board rotation. Alan Holmer’s decade-plus tenure as founding Chair was stable and foundational, but the company is entering what CEO Yuval Cohen describes as an “exciting new chapter.” Jacques’ appointment represents both continuity—she remains on the Board—and momentum, injecting fresh strategic perspective when the company needs it most.

This transition pattern is not uncommon in biotech. As companies mature from early development to clinical-stage operations approaching data readouts, boards often seek chairs with commercialization expertise and regulatory success. Jacques’ experience with FDA approvals and launch strategy suggests the Board is preparing Corbus for potential next phases, assuming clinical trials deliver positive results.

Pipeline Dreams and Market Skepticism

Here’s where things get interesting. Corbus’ pipeline includes three candidates: CRB-701 (a next-generation antibody drug conjugate targeting Nectin-4 for oncology), CRB-601 (an anti-integrin monoclonal antibody blocking TGFβ activation for cancer), and CRB-913 (a CB1 receptor inverse agonist for obesity treatment). Clinical readouts for all three are expected in the second half of 2025—a concentrated timeline that could either validate the company’s strategy or expose significant setbacks.

The obesity space particularly deserves attention. With companies like Novo Nordisk and Eli Lilly dominating the GLP-1 market, Corbus’ differentiated CB1 approach could carve a niche—or face an uphill battle against established players. The oncology programs target aggressive cancers, a space crowded with innovative treatments but perpetually hungry for better options.

Market reaction has been mixed. During the first quarter of 2025, institutional investors showed split sentiment: Octagon Capital Advisors significantly increased their position by 2.4 million shares (adding approximately $12.9 million), suggesting confidence in the pipeline. However, larger investors like Adage Capital Partners completely exited their positions, trimming roughly 529,000 shares. This divergence—simultaneous buying and selling among sophisticated investors—reflects genuine uncertainty about clinical outcomes.

What Wall Street Really Thinks

Recent analyst coverage offers cautious optimism. B. Riley issued a “Buy” rating in early May 2025, while Piper Sandler maintained an “Overweight” rating from late 2024. The fact that two firms are bullish while none have issued sell ratings suggests the Street isn’t bearish, though the limited number of published ratings indicates modest coverage depth.

Insider trading activity provides another lens on management confidence. Over the past six months through early 2025, Corbus insiders completed three transactions—all sales. CEO Yuval Cohen sold approximately 7,134 shares for roughly $62,464, Chief Medical Officer Dominic Smethurst sold about 6,393 shares for $43,329, and CFO Sean Moran sold 2,792 shares for approximately $24,446. Zero purchases and three sales might suggest executives are cautious about near-term prospects, or simply managing their equity holdings during a period of volatility.

The Road Ahead for Corbus Under Jacques’ Helm

Jacques herself has emphasized her strategic priorities. “Our targeted oncology programs are designed to strike at the heart of aggressive cancers,” she noted upon appointment, “while our obesity program has the potential to address one of the most urgent public health challenges of our time.” This framing—positioning Corbus as addressing genuine unmet medical needs rather than just chasing market trends—reflects her vision for the company.

The second half of 2025 will be definitive. If clinical data from CRB-701, CRB-601, and CRB-913 meet expectations, Jacques’ leadership could accelerate the company toward regulatory pathways and potential partnerships or acquisitions. If results disappoint, even fresh strategic leadership can’t overcome fundamental science. The Board Chair role, particularly when filled by someone with Jacques’ regulatory and commercialization pedigree, often signals management’s confidence that positive data is imminent.

Corbus Pharmaceuticals entered 2025 at an inflection point. With Rachelle Jacques now steering Board strategy and clinical readouts looming, the company’s narrative is about to be rewritten—for better or worse. Investors watching the space should mark their calendars for mid-to-late 2025 when those pipeline readouts arrive.